Vascular endothelial growth factor (VEGF) is a potent promoter of angiogene
sis that has been shown to enhance revascularization of ischemic tissues, i
ncluding skin flaps. This study was designed to investigate the value of a
single topical application of recombinant human VEGF to accelerate flap via
bility in a rat model of a non-ischemic prefabricated flap. Prefabricated f
laps were created in 48 Sprague-Dawley rats. An autologous tail artery loop
was anastomosed to the femoral artery and vein, and implanted subcutaneous
ly in the lower abdomen. Flaps were divided into two groups of 24 each. At
the time of loop implantation, the control group received 0.9 percent NaCl
or a 16 percent vol/wet polyvinyl alcohol (PVA) solution; the treatment gro
up received VEGF in 0.9 percent NaCl or VEGF in PVA. The PVA gel was used t
o facilitate topical application. In each group, 3- X 4-cm flaps nurtured b
y the tail artery pedicle were elevated and resutured into place after 3, 4
, and 5 weeks. The percentage of surviving skin of each flap was determined
by planimetry 7 days after flap elevation. Mean skin survival areas at 3,
4, and 5 weeks were: control group, 0 percent, 8 percent, and 17.5 percent;
and VEGF-treated group, 6 percent, 40 percent, and 66.7 percent, respectiv
ely. VEGF significantly improved flap survival by 5 weeks (p = 0.02). These
results suggest that VEGF can accelerate maturation of prefabricated flaps
. This approach could expand the application of flap prefabrication as a re
source for reconstructive surgery.